Position
Renaissance Technologies in Entrada Therapeutics, Inc.
Back to the book · All holders of TRDA
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$1M$12.62 → $7.36
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 252.6K | $2.6M | — | — | — | 0.0% |
| Q1 2026 | 202.1K | $2.55M | $12.62 | $472.9K | −$519.7K | 0.0% |
| Q2 2026 | 191K | $1.41M | $7.36 | −$1M | −$139.9K | 0.0% |